Business Context and Reporting Period
This Form 8-K is filed by BioSig Technologies, Inc. (not Streamex Corp.) with a report date of March 31, 2017. The filing discloses the consummation of unregistered sales of equity securities through private placement offerings to accredited investors.
Key Financial Metrics and Transaction Details
The filing details two specific closings of private placements involving the sale of units (common stock and warrants) at a price of $1.50 per unit.
- Total Aggregate Consideration: $1,111,750 raised from the transactions reported in this filing.
- Total Common Stock Issued: 741,167 shares.
- Total Warrants Issued: 370,584 warrants (exercisable at $1.50/share).
- April 6, 2017 Closing: Raised $640,000 for 426,667 units (426,667 shares + 213,334 warrants).
- March 31, 2017 Closing: Raised $471,750 for 314,500 units (314,500 shares + 157,250 warrants).
Note: The filing does not provide data on revenue, operating profit, cash flow, margins, or existing debt levels. Proceeds are designated for general corporate purposes, growth initiatives, and capital expenditures.
Material Changes and Historical Context
The March 31, 2017 closing represents the seventh closing under a Unit Purchase Agreement dated October 28, 2016. The filing references prior closings that occurred between October 2016 and March 2017, indicating a sustained capital raise effort over several months. The total capital raised under the October Purchase Agreement prior to this filing was approximately $3,878,203.
Guidance, Risks, and Contractual Obligations
Use of Proceeds: The Company is contractually prohibited from using proceeds to repay debt, redeem equity, or settle claims. Funds must be used for growth and capital expenditures.
Registration Rights and Penalties: The Company must file a registration statement within 45 days of the final closing to allow investors to resell shares. Failure to file or maintain effectiveness triggers liquidated damages of 1% of the purchase price per 30-day period of delinquency, capped at 6%, plus 18% annual interest on unpaid amounts.
Warrant Terms: Warrants are immediately exercisable at $1.50 and expire on April 6, 2020. They include anti-dilution protections and a beneficial ownership limitation of 4.99% (expandable to 9.99% with notice).
Risks: The securities were sold unregistered under Section 4(a)(2) and Rule 506. The Company must maintain continuous reporting status under the Exchange Act to satisfy investor covenants.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance to assess dilution impact.
- Confirm the filing date and effectiveness status of the required registration statement for the new shares.
- Review the Company's cash position to ensure proceeds are being utilized for stated growth initiatives rather than debt service.
- Check for any subsequent filings regarding the liquidated damages clause if registration deadlines are missed.
- Validate the Company's continued compliance with Exchange Act reporting requirements as mandated by the purchase agreements.